Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. Thi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Formisano, Luigi, Lu, Yao, Servetto, Alberto, Hanker, Ariella B., Jansen, Valerie M., Bauer, Joshua A., Sudhan, Dhivya R., Guerrero-Zotano, Angel L., Croessmann, Sarah, Guo, Yan, Ericsson, Paula Gonzalez, Lee, Kyung-min, Nixon, Mellissa J., Schwarz, Luis J., Sanders, Melinda E., Dugger, Teresa C., Cruz, Marcelo Rocha, Behdad, Amir, Cristofanilli, Massimo, Bardia, Aditya, O’Shaughnessy, Joyce, Nagy, Rebecca J., Lanman, Richard B., Solovieff, Nadia, He, Wei, Miller, Michelle, Su, Fei, Shyr, Yu, Mayer, Ingrid A., Balko, Justin M., Arteaga, Carlos L.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6435685/
https://ncbi.nlm.nih.gov/pubmed/30914635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09068-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados